Inactive Instrument

XsunX Inc Stock price OTC Bulletin Board

Equities

US98385L1026

Biotechnology & Medical Research

Sales 2022 - Sales 2023 - Capitalization 2.17M
Net income 2022 -1M Net income 2023 -4M EV / Sales 2022 -
Net Debt 2022 1.41M Net Debt 2023 2.36M EV / Sales 2023 -
P/E ratio 2022
-1.16 x
P/E ratio 2023
-0.43 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 34.82%
More Fundamentals * Assessed data
Dynamic Chart
NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLC CI
NovAccess Global Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory Board CI
NovAccess Global Inc. announced that it expects to receive $10.68 million in funding from Sumner Capital Pty Ltd. CI
NovAccess Global Inc. announced that it expects to receive $0.055 million in funding CI
NovAccess Global Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
NovAccess Global Inc. Partners with BCN Biosciences to Expand Immunotherapy Platform CI
NovAccess Global Inc. announced that it has received $0.055 million in funding from 1800 Diagonal Lending, LLC CI
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division CI
NovAccess Global Inc. Enters into a Letter Agreement with AJB Capital Investments, LLC CI
NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare Therapies CI
NovAccess Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
NovAccess Global Inc. announced that it has received $0.05425 million in funding from 1800 Diagonal Lending, LLC CI
NovAccess Global Inc. announced that it expects to receive $0.05425 million in funding from 1800 Diagonal Lending, LLC CI
More news
Managers TitleAgeSince
Chief Executive Officer 56 20-10-14
Director of Finance/CFO 70 21-09-09
Members of the board TitleAgeSince
Chief Executive Officer 56 20-10-14
Director/Board Member 50 22-03-17
Chairman 57 22-03-13
More insiders
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.
More about the company
  1. Stock
  2. Equities
  3. Stock NovAccess Global Inc.
  4. Stock XsunX Inc - OTC Bulletin Board